Oncomine Grants Clinical Research Program overview

Current Call for Applications

The Oncomine Clinical Research Grant Program is currently accepting proposals addressing unmet diagnostic needs using next-generation sequencing for both solid and hematological cancers. Studies aiming to demonstrate the value of fast complete molecular diagnostics are warmly welcome, equally as projects addressing needs in pediatric cancers.

Grant submissions are currently closed. Please check back for the next open enrollment period.

Submitting Your Application

Proposals will be accepted through the submission portal. Alternatively we may accept via the email medical.affairs@thermofisher.com. Please visit this web page during the open submission period to submit your application.

Read our blog for tips on how to submit a strong grant application.

About the Oncomine Clinical Research Grant Program

The Oncomine Clinical Research Grant Program supports investigator-initiated studies (IIS) and education projects, on molecular profiling in oncology, with the goal to increase high quality molecular profiling and to help democratize the future of precision medicine.

Proposal reviews are conducted by independent and internationally recognized experts together with Thermo Fisher Scientific medical and scientific leadership. Funding is considered based on scientific merit.

The application process is managed by the Oncomine Clinical Research Grant Office, part of the Medical Affairs team of the Clinical Sequencing Division at Thermo Fisher Scientific. For detailed information about how to apply, including documentation requirements, review process, and decision notification, refer to the Guidelines for Applicants.   

Grant applications should be submitted electronically (English only) using the specific Proposal Form. Proposals should outline the planned activities to be performed within a maximum of 12 months. A budget is required for every grant request and should detail the proposed use of requested funds. The maximum budget request for each project is set at $200,000.

More Information:

From the Awardees

“The Oncomine Grant program gives a chance to those who wouldn’t otherwise have it to be able to work with next-generation sequencing technologies. The funding from the Oncomine Grant program can really help us overcome one of the biggest hurdles for smaller and less funded centers to be able to work with these types of emerging technologies.”

Brandon Sheffield, MD
William Osler Health System, Canada
2020 Oncomine Clinical Research Grant awardee

“Industry funding [like the Oncomine Clinical Research Grant program] is important because it can generate a sort of virtual circle, creating a link between the industry and different academic institutions and hospital research labs, and this link can foster the development and the implementation of new platforms or new assays focused on the unmet clinical needs of the future.”

Elena Guerini Rocco, MD
European Institute of Oncology IRCCS, Italy
2021 Oncomine Clinical Research Grant awardee

“The opportunity the Oncomine Grant has afforded us to work on the analysis of the
T cell repertoire has opened also a number of opportunities for my team to collaborate
on larger studies. We are now moving from the analysis that we have done with the Oncomine Grant to a large study at the national level to further evaluate these biomarkers and the T cell repertoire.”

Elin Gray, PhD
Edith Cowan University, Australia
2021 Oncomine Clinical Research Grant awardee

Grant Selection Process Overview

The evaluation process is performed by a committee of external experts in the field, along with Thermo Fisher Scientific medical and scientific leadership. The committee selects awardees based on the scientific merit of the proposed project.

Step 1: Submission

Submission is done by sending the proposal form to the following email address: medical.affairs@thermofisher.com or using the online grant management portal.

Step 2: Evaluation

Submissions are confirmed by the grant office via email. Decisions are communicated 6 to 8 weeks after the closing date of the call.

Step 3: Execution

Upon contract signature, the requested support will be granted. The grant office team will continue to support the development of the awarded project. A final report is due to the grant office team within the agreed time frame.

2022 Oncomine Grant Awardees

We thank all applicants that submitted projects across our 2022 calls for applications.

We are pleased to announce the 2022 grant awardees below.

Matias Avila, B. Pharm., Ph.D

Carmen Berasain, Ph.D

University of Navarra, Pamplona, Spain

“Mutational Analysis of Bile cfDNA for the Early Diagnosis of Biliopancreatic Tumors”

Wendy Erber, MD

The University of Western Australia, Crawley, Australia

“Genomic Profiling and Disease Monitoring Using Plasma Cell-Free DNA in Acute Myeloid Leukemia”

Xiuning Le, MD, PhD

MD Anderson Cancer Center, Houston, U.S.A.

“ctDNA Analysis to Understand Resistance and Response to ORC Therapy in EGFR Mutant Non-Small Cell Lung Cancer”

Nir Peled, MD, PhD, FCCP

Shaare Zedek Medical Center, Jerusalem, Israel

“Liquid Biopsy in Suspected Lung Cancer Solitary Pulmonary Nodules”

Dr. Monica Lopez-Guerra, PhD

Hospital Clinic, Barcelona, Spain

“Molecular measurable residual disease (MRD) monitoring by high-throughput techniques in patients with CART 19 therapy”

Prof. Estrid Høgdall, PhD

Herlev University Hospital, Herlev, Denmark

“HRD biomarker: Qualification and implementation of validated local HRD test”

Prof. Dr. Paul Hofman, PhD

University of Côte d’Azur, France

“Comprehensive molecular characterization of early stage NSCLC with KRAS G12C mutation using ODxET”

See past grant awardees